GSK: 2026 Looks Good

Manika PremsinghInvesting GroupFollow5ShareSavePlay(8min)CommentsSummaryGSK has surged ~46% YTD, far outpacing both the healthcare sector and S&P 500, which is notable considering the spectre of high US tariffs hanging over it.The recent US-UK pharmaceuticals deal, the company's investment plans in the US, and the likelihood of a possible drug pricing agreement with the US government can work for GSK.Supporting these developments is the company's solid financial performance, upgraded outlook and attractive market multiples. 13threephotography/iStock Editorial via Getty Images It has been a very good year for the British pharmaceutical stock GSK plc (GSK), which is up by ~46% YTD. This far exceeds the performance of the healthcare sector, as evident from the 13.5% returns on the This article was written byManika Premsingh4.33K FollowersFollowManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants, takes the theme a step further from LTT with a deeper dive into opportunities presented by the segment.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in GSK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.